Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04215809 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 10, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 35 to 144 Primary completion date: Mar 30, 2025 to Oct 31, 2025 · Completion date: Jun 30, 2026 to Jun 30, 2027 · Interventions: APG2575 (Drug) to Lisaftoclax (Drug) · 3 morev11 Show 6 more changesShow less
    • Primary completion date: Mar 30, 2025 to Oct 31, 2025
    • Completion date: Jun 30, 2026 to Jun 30, 2027
    • Interventions: APG2575 (Drug) to Lisaftoclax (Drug)
    • Eligibility criteria expanded, about 57 words
    • Study arms: 6 to 4
    • Study description shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Dec 30, 2022 to Mar 30, 2025 Completion date: Jan 30, 2023 to Jun 30, 2026v10 Show 1 more changeShow less
    • Completion date: Jan 30, 2023 to Jun 30, 2026
  3. Primary completion date: Dec 30, 2021 to Dec 30, 2022 Completion date: Jan 30, 2022 to Jan 30, 2023v9 Show 1 more changeShow less
    • Completion date: Jan 30, 2022 to Jan 30, 2023
  4. Study sites: 7 to 9v8
  5. Site details revised at 5 of 7 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jan 30, 2021 to Dec 30, 2021 Study sites: 8 to 7v6 Show 1 more changeShow less
    • Study sites: 8 to 7
  2. Study sites: 11 to 8v5
  3. Site details revised at 1 of 11 sitesv4
  4. Study sites: 1 to 11v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jan 30, 2020 to Mar 2, 2020v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 30, 2020 to Mar 2, 2020
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.
Trial Details
NCT Number NCT04215809
Lead Sponsor Ascentage Pharma Group Inc.
Conditions CLL/SLL
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov